Gonasi

Gonasi is a prescription medication that contains the active ingredient Human Chorionic Gonadotropin (hCG). It is supplied in an injectable form for intramuscular or subcutaneous administration, and is marketed in the European Union. Gonasi functions as a gonadotropin analog, mimicking luteinizing hormone activity to support reproductive processes in both women and men. The product is typically prescribed by specialists in fertility and endocrinology and is regulated as a prescription‑only drug.

Gonasi is used in several reproductive‑health indications where stimulation of luteinizing hormone pathways is required.

- Induction of ovulation in women with anovulatory infertility, often as part of assisted reproductive protocols. - Luteal phase support following in‑vitro fertilization or embryo transfer to enhance implantation success. - Stimulation of endogenous testosterone production in men with hypogonadotropic hypogonadism. - Treatment of cryptorchidism in pediatric patients to promote testicular descent. - Adjunct therapy in certain cases of delayed puberty where gonadotropin deficiency is identified.

Side‑effect profiles for hCG products such as Gonasi reflect the hormone’s physiological actions and the route of injection.

Common: - Injection‑site pain, redness, or swelling. - Transient headache or mild flu‑like symptoms. - Mood changes or mild irritability.

Serious: - Ovarian hyperstimulation syndrome (OHSS) with abdominal distension, rapid weight gain, or shortness of breath. - Allergic reactions ranging from urticaria to anaphylaxis. - Thromboembolic events, particularly in patients with pre‑existing clotting disorders.

Clinicians should evaluate patient history and risk factors before prescribing Gonasi to minimize adverse outcomes.

- Confirm pregnancy status; hCG is contraindicated in established pregnancy except for specific luteal support. - Assess for ovarian cysts or polycystic ovary syndrome, which increase OHSS risk. - Review cardiovascular and thrombotic risk, especially in smokers or those with clotting disorders. - Monitor serum estradiol and ovarian response during stimulation cycles. - Use caution in patients with known hypersensitivity to hCG or any formulation components. - Adjust dose in pediatric patients according to weight and clinical response.

Gonasi may interact with other medications or hormonal agents, influencing efficacy or safety.

Avoid: - Concurrent use of estrogen‑containing contraceptives or hormone therapy that may blunt hCG response. - High‑dose gonadotropin‑releasing hormone (GnRH) agonists without appropriate timing, which can alter ovulation outcomes.

Use with caution: - Anticoagulants or antiplatelet drugs, due to potential increased bleeding at injection sites. - Thyroid hormone replacement, as hCG can affect thyroid function tests. - Steroid medications that may modify hormonal balance. - Diuretics, because fluid shifts can exacerbate OHSS symptoms.